Margaret A. Alexander - 23 Feb 2026 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
President and CEO, Director
Signature
/s/ Jeffrey Rona, Attorney-in-Fact
Issuer symbol
OVID
Transactions as of
23 Feb 2026
Net transactions value
-$16,901
Form type
4
Filing time
02 Mar 2026, 16:30:24 UTC
Previous filing
05 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ALEXANDER MARGARET A. President and CEO, Director C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, 14TH FLOOR, NEW YORK /s/ Jeffrey Rona, Attorney-in-Fact 02 Mar 2026 0002036798

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OVID Common Stock Sale $16,901 -11,656 -16% $1.45 61,750 23 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Employee Stock Option (Right to Buy) Award $0 +1,435,000 $0.000000 1,435,000 26 Feb 2026 Common Stock 1,435,000 $1.65 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.